aibio
Company Updates ·
Emmaus appoints Henry Du to its board and audit committee
Henry H. Du, a certified public accountant and interim chief financial officer of Alpha Cognition, fills the board seat left by the resignation of Jon Kuwahara.
ACOG Alpha Cognition Inc.
Alpha Cognition (ACOG) news ACOG offering news
Latest Alpha Cognition news
- Financings
Alpha Cognition prices $34,999,052 public offering of shares at $6.25
Alpha Cognition priced 4,651,516 common shares and pre-funded warrants for 948,484 shares at $6.25 and $6.249, for a total of $34,999,052 before fees. Titan Partners Group is the sole bookrunner, and the company says the money will fund a sales push for ZUNVEYL.
What Alpha Cognition does
Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases, such as Alzheimer's disease, for which the company says there are limited or no treatment options. Its lead product is ZUNVEYL, an oral delayed release tablet formulation that the FDA approved on July 26, 2024 for mild to moderate dementia of the Alzheimer's type. The company describes ZUNVEYL as a next generation acetylcholinesterase inhibitor whose active metabolite binds neuronal nicotinic receptors, most notably the alpha-7 subtype. ZUNVEYL launched on March 19, 2025, with a specialty sales force targeting long-term care physicians and nursing homes that specialize in Alzheimer's disease. The company is pursuing formulary coverage with U.S. payors and pharmacy benefit managers and expects to seek distribution partners in Europe, LATAM, the Middle East and Asia. Its pre-clinical programs include ZUNVEYL with memantine for moderate to severe Alzheimer's disease, an ALPHA-1062 sublingual formulation for cognitive impairment with mild traumatic brain injury, and a benzgalantamine sublingual formulation for mild-to-moderate Alzheimer's disease. The company terminated its licensing agreement for two progranulin programs, which it describes as preclinical.
| Product or program | What it is | Stage |
|---|---|---|
| ZUNVEYL | Oral delayed release tablet for mild to moderate dementia of the Alzheimer's type | FDA approved July 26, 2024; launched March 19, 2025 |
| ZUNVEYL with memantine | Combination for moderate to severe Alzheimer's disease | Pre-clinical |
| ALPHA-1062 sublingual formulation | Sublingual formulation for cognitive impairment with mild traumatic brain injury | Pre-clinical |
| Benzgalantamine sublingual formulation | Sublingual formulation for mild-to-moderate Alzheimer's disease |
Alpha Cognition annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $10.2 million | |
| Research and development | $1.9 million | $3.9 million |
| Net income (loss) | -$20.7 million | -$14.8 million |
| Cash from operations | -$20.4 million | -$7.8 million |
| Cash and equivalents | $66.0 million | $48.5 million |
Questions about Alpha Cognition
Has Alpha Cognition raised money recently?
Our latest story on this, dated Sep 30, 2025: "Alpha Cognition prices $34,999,052 public offering of shares at $6.25". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Alpha Cognition?
Alpha Cognition Inc. trades under the ticker ACOG on NASDAQ.
Where is Alpha Cognition listed?
Alpha Cognition Inc. is listed on NASDAQ.
What is the SEC CIK of Alpha Cognition?
The SEC Central Index Key (CIK) for Alpha Cognition Inc. is 1655923. Its filings are on SEC EDGAR.
How many shares does Alpha Cognition have outstanding?
21,777,868 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Alpha Cognition listed under?
Our directory records Alpha Cognition Inc. under United States.
What does Alpha Cognition do?
Our directory classifies Alpha Cognition Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of Alpha Cognition?
The ISIN recorded for Alpha Cognition Inc. is CA02074J5017.
Does aibio.space cover Alpha Cognition?
aibio.space lists Alpha Cognition Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Alpha Cognition incorporated?
SEC records list its state or country of incorporation as A1.
What does Alpha Cognition develop?
Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases, such as Alzheimer's disease, for which the company says there are limited or no treatment options. Its lead product is ZUNVEYL, an oral delayed release tablet formulation that the FDA approved on July 26, 2024 for mild to moderate dementia of the Alzheimer's type.
What is ZUNVEYL from Alpha Cognition?
ZUNVEYL: Oral delayed release tablet for mild to moderate dementia of the Alzheimer's type Stage: FDA approved July 26, 2024; launched March 19, 2025.
What is ZUNVEYL with memantine from Alpha Cognition?
ZUNVEYL with memantine: Combination for moderate to severe Alzheimer's disease Stage: Pre-clinical.
What was Alpha Cognition's revenue last year?
$10.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Alpha Cognition profitable?
Alpha Cognition Inc. reported a net loss of $20.7 million for the fiscal year ended Dec 31, 2025, and used $20.4 million of cash in operations, per its annual report to the SEC.
Investor discussion: Alpha Cognition
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form S-3. Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
- Financings
Reported a financing. SEC Form 424B4. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Alpha Cognition Inc.
- CIK
- 1655923
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- ACOG (Nasdaq)
- State or country of incorporation
- A1
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Business address
- 1452 HUGHES RD., STE. 200, GRAPEVINE, TX, 76051
- Phone
- (858) 344-4375
- Shares outstanding
- 21,777,868 as of 2026-08-13 (10-Q filed 2026-08-13)
- Former names
- Neurodyn Cognition Inc.
Recent filings
Listing details
- Company
- Alpha Cognition Inc.
- Ticker
- ACOG
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biopharma / pharmaceuticals
- ISIN
- CA02074J5017
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction